hrp0097p1-198 | Thyroid | ESPE2023

Graves’ disease in children with Down syndrome

Nurcan Cebeci Ayse , Schempp Vera , Reinauer Christina , Gohlke Bettina , Marx Michaela , Dörr Helmuth-Günther , Woelfle Joachim

Introduction: Thyroid abnormalities such as subclinical or overt hypothyroidism are common in children with Down syndrome (DS) with ranges from 4% to 19.5%, whereas Graves´ disease (GD) is extremely rare (ranges 0.6%-0.9 %).Aims: To evaluate clinical features, course, and treatment of GD in children with DS.Patients and Methods: Among 161 children with GD, diagnosed between 1...

hrp0098p3-254 | Thyroid | ESPE2024

Chief complaints at initial presentation of children with Graves’ disease

Nurcan Cebeci Ayse , Schempp Vera , Förtsch Katharina , Gohlke Bettina , Marx Michaela , Dörr Helmuth-Günther , Woelfle Joachim

Introduction: Children with Graves' disease (GD) show a set of characteristic clinical symptoms but data describing the chief complaints that led to the initial presentation are rare.Aims: To evaluate the spectrum of complaints of children with GD at initial presentation.Patients and Methods: We performed a retrospective review of the medical records of 148 children with bioch...

hrp0097p1-388 | Thyroid | ESPE2023

Neutropenia in paediatric Graves disease patients occurs more often under Carbimazole than Methimazole

Schempp Vera , Nurcan Cebeci Ayse , Reinauer Christina , Woelfle Joachim , Dörr Helmuth-Günther , Roosen Marie-Thérèse , Gohlke Jonas , Gohlke Bettina

Introduction: Neutropenia is known as a rare adverse event of anti-thyroid drug treatment (ATD) but has also been reported as pre-treatment neutropenia in Graves’ disease (GD). Studies on paediatric patients are rare. To the best of our knowledge, there are no data comparing the effects of methimazole (MMI) and carbimazole (CBZ) treatment in children on the absolute neutrophil count (ANC).Methods: We analyzed retro...